Does the media favor KURA or IRON?

In the previous week, Disc Medicine had 2 more articles in the media than Kura Oncology. MarketBeat recorded 4 mentions for Disc Medicine and 2 mentions for Kura Oncology. Kura Oncology's average media sentiment score of 0.55 beat Disc Medicine's score of 0.26 indicating that Kura Oncology is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kura Oncology 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Disc Medicine 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is JANX or IRON more profitable?

Janux Therapeutics' return on equity of -11.89% beat Disc Medicine's return on equity. Company Net Margins Return on Equity Return on Assets Janux Therapeutics N/A -11.89% -11.13% Disc Medicine N/A -37.17% -33.65%

Does the media favor JANX or IRON?

In the previous week, Disc Medicine had 1 more articles in the media than Janux Therapeutics. MarketBeat recorded 4 mentions for Disc Medicine and 3 mentions for Janux Therapeutics. Disc Medicine's average media sentiment score of 0.26 beat Janux Therapeutics' score of -0.08 indicating that Disc Medicine is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Janux Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Disc Medicine 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor IRON or ABUS?

In the previous week, Disc Medicine had 3 more articles in the media than Arbutus Biopharma. MarketBeat recorded 4 mentions for Disc Medicine and 1 mentions for Arbutus Biopharma. Arbutus Biopharma's average media sentiment score of 1.73 beat Disc Medicine's score of 0.26 indicating that Arbutus Biopharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Disc Medicine 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Arbutus Biopharma 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Which has higher valuation and earnings, IRON or ANL?

Adlai Nortye has higher revenue and earnings than Disc Medicine. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Disc Medicine N/A N/A -$212.18M -$6.58 N/A Adlai Nortye $5M 206.53 -$35.53M N/A N/A

Is IRON or ANL more profitable?

Adlai Nortye's return on equity of 0.00% beat Disc Medicine's return on equity. Company Net Margins Return on Equity Return on Assets Disc Medicine N/A -37.17% -33.65% Adlai Nortye N/A N/A N/A

Does the media favor IRON or ANL?

In the previous week, Disc Medicine had 1 more articles in the media than Adlai Nortye. MarketBeat recorded 4 mentions for Disc Medicine and 3 mentions for Adlai Nortye. Adlai Nortye's average media sentiment score of 0.92 beat Disc Medicine's score of 0.26 indicating that Adlai Nortye is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Disc Medicine 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Adlai Nortye 2 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better valuation and earnings, SANA or IRON?

Disc Medicine is trading at a lower price-to-earnings ratio than Sana Biotechnology, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Sana Biotechnology N/A N/A -$244.17M -$0.76 N/A Disc Medicine N/A N/A -$212.18M -$6.58 N/A

Is SANA or IRON more profitable?

Disc Medicine's return on equity of -37.17% beat Sana Biotechnology's return on equity. Company Net Margins Return on Equity Return on Assets Sana Biotechnology N/A -103.02% -39.16% Disc Medicine N/A -37.17% -33.65%

Does the media refer more to SANA or IRON?

In the previous week, Disc Medicine had 1 more articles in the media than Sana Biotechnology. MarketBeat recorded 4 mentions for Disc Medicine and 3 mentions for Sana Biotechnology. Sana Biotechnology's average media sentiment score of 0.42 beat Disc Medicine's score of 0.26 indicating that Sana Biotechnology is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sana Biotechnology 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Disc Medicine 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Disc Medicine (IRON) Competitors

$65.66 -2.83 (-4.13%)

As of 02:35 PM Eastern

Compare

IRON vs. KURA, JANX, ABUS, ANL, and SANA

Should you buy Disc Medicine stock or one of its competitors? Disc Medicine's main competitors and comparable companies include Kura Oncology (KURA), Janux Therapeutics (JANX), Arbutus Biopharma (ABUS), Adlai Nortye (ANL), and Sana Biotechnology (SANA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Disc Medicine compare to Kura Oncology?

Kura Oncology (NASDAQ:KURA) and Disc Medicine (NASDAQ:IRON) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, risk, profitability, dividends, valuation, media sentiment, analyst recommendations and institutional ownership.

In the previous week, Disc Medicine had 2 more articles in the media than Kura Oncology. MarketBeat recorded 4 mentions for Disc Medicine and 2 mentions for Kura Oncology. Kura Oncology's average media sentiment score of 0.55 beat Disc Medicine's score of 0.26 indicating that Kura Oncology is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kura Oncology	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Disc Medicine	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

83.7% of Disc Medicine shares are owned by institutional investors. 7.6% of Kura Oncology shares are owned by company insiders. Comparatively, 3.8% of Disc Medicine shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Disc Medicine has lower revenue, but higher earnings than Kura Oncology. Disc Medicine is trading at a lower price-to-earnings ratio than Kura Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kura Oncology	$67.48M	14.62	-$278.67M	-$3.37	N/A
Disc Medicine	N/A	N/A	-$212.18M	-$6.58	N/A

Kura Oncology currently has a consensus target price of $25.40, suggesting a potential upside of 129.04%. Disc Medicine has a consensus target price of $110.18, suggesting a potential upside of 67.93%. Given Kura Oncology's higher possible upside, equities research analysts plainly believe Kura Oncology is more favorable than Disc Medicine.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kura Oncology	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75
Disc Medicine	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.77

Kura Oncology has a beta of 0.44, indicating that its stock price is 56% less volatile than the broader market. Comparatively, Disc Medicine has a beta of 0.97, indicating that its stock price is 3% less volatile than the broader market.

Disc Medicine has a net margin of 0.00% compared to Kura Oncology's net margin of -384.30%. Disc Medicine's return on equity of -37.17% beat Kura Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kura Oncology	-384.30%	-207.18%	-45.17%
Disc Medicine	N/A	-37.17%	-33.65%

Summary

Disc Medicine beats Kura Oncology on 9 of the 15 factors compared between the two stocks.

How does Disc Medicine compare to Janux Therapeutics?

Janux Therapeutics (NASDAQ:JANX) and Disc Medicine (NASDAQ:IRON) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their profitability, institutional ownership, valuation, risk, analyst recommendations, media sentiment, earnings and dividends.

75.4% of Janux Therapeutics shares are held by institutional investors. Comparatively, 83.7% of Disc Medicine shares are held by institutional investors. 7.9% of Janux Therapeutics shares are held by company insiders. Comparatively, 3.8% of Disc Medicine shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Disc Medicine had 1 more articles in the media than Janux Therapeutics. MarketBeat recorded 4 mentions for Disc Medicine and 3 mentions for Janux Therapeutics. Disc Medicine's average media sentiment score of 0.26 beat Janux Therapeutics' score of -0.08 indicating that Disc Medicine is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Janux Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Disc Medicine	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Janux Therapeutics has higher revenue and earnings than Disc Medicine. Janux Therapeutics is trading at a lower price-to-earnings ratio than Disc Medicine, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Janux Therapeutics	$10M	101.19	-$113.62M	-$1.64	N/A
Disc Medicine	N/A	N/A	-$212.18M	-$6.58	N/A

Janux Therapeutics presently has a consensus target price of $36.46, indicating a potential upside of 120.30%. Disc Medicine has a consensus target price of $110.18, indicating a potential upside of 67.93%. Given Janux Therapeutics' higher probable upside, research analysts plainly believe Janux Therapeutics is more favorable than Disc Medicine.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Janux Therapeutics	2 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.67
Disc Medicine	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.77

Janux Therapeutics has a beta of 2.53, indicating that its stock price is 153% more volatile than the broader market. Comparatively, Disc Medicine has a beta of 0.97, indicating that its stock price is 3% less volatile than the broader market.

Janux Therapeutics' return on equity of -11.89% beat Disc Medicine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Janux Therapeutics	N/A	-11.89%	-11.13%
Disc Medicine	N/A	-37.17%	-33.65%

Summary

Janux Therapeutics beats Disc Medicine on 9 of the 15 factors compared between the two stocks.

How does Disc Medicine compare to Arbutus Biopharma?

Disc Medicine (NASDAQ:IRON) and Arbutus Biopharma (NASDAQ:ABUS) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, risk, profitability, dividends, analyst recommendations, earnings, institutional ownership and valuation.

83.7% of Disc Medicine shares are owned by institutional investors. Comparatively, 43.8% of Arbutus Biopharma shares are owned by institutional investors. 3.8% of Disc Medicine shares are owned by company insiders. Comparatively, 19.9% of Arbutus Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Arbutus Biopharma has higher revenue and earnings than Disc Medicine. Disc Medicine is trading at a lower price-to-earnings ratio than Arbutus Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Disc Medicine	N/A	N/A	-$212.18M	-$6.58	N/A
Arbutus Biopharma	$14.08M	69.16	-$33.50M	$0.79	6.22

Arbutus Biopharma has a net margin of 84.22% compared to Disc Medicine's net margin of 0.00%. Arbutus Biopharma's return on equity of 90.98% beat Disc Medicine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Disc Medicine	N/A	-37.17%	-33.65%
Arbutus Biopharma	84.22%	90.98%	82.34%

Disc Medicine has a beta of 0.97, meaning that its stock price is 3% less volatile than the broader market. Comparatively, Arbutus Biopharma has a beta of 0.62, meaning that its stock price is 38% less volatile than the broader market.

In the previous week, Disc Medicine had 3 more articles in the media than Arbutus Biopharma. MarketBeat recorded 4 mentions for Disc Medicine and 1 mentions for Arbutus Biopharma. Arbutus Biopharma's average media sentiment score of 1.73 beat Disc Medicine's score of 0.26 indicating that Arbutus Biopharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Disc Medicine	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Arbutus Biopharma	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Disc Medicine currently has a consensus price target of $110.18, suggesting a potential upside of 67.93%. Arbutus Biopharma has a consensus price target of $5.00, suggesting a potential upside of 1.73%. Given Disc Medicine's stronger consensus rating and higher probable upside, research analysts plainly believe Disc Medicine is more favorable than Arbutus Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Disc Medicine	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.77
Arbutus Biopharma	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50

Summary

Arbutus Biopharma beats Disc Medicine on 9 of the 15 factors compared between the two stocks.

How does Disc Medicine compare to Adlai Nortye?

Disc Medicine (NASDAQ:IRON) and Adlai Nortye (NASDAQ:ANL) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, analyst recommendations, earnings, valuation, profitability, dividends, media sentiment and institutional ownership.

83.7% of Disc Medicine shares are owned by institutional investors. Comparatively, 35.2% of Adlai Nortye shares are owned by institutional investors. 3.8% of Disc Medicine shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Disc Medicine currently has a consensus target price of $110.18, indicating a potential upside of 67.93%. Adlai Nortye has a consensus target price of $29.50, indicating a potential upside of 83.97%. Given Adlai Nortye's higher possible upside, analysts clearly believe Adlai Nortye is more favorable than Disc Medicine.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Disc Medicine	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.77
Adlai Nortye	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

Disc Medicine has a beta of 0.97, indicating that its share price is 3% less volatile than the broader market. Comparatively, Adlai Nortye has a beta of 1.04, indicating that its share price is 4% more volatile than the broader market.

In the previous week, Disc Medicine had 1 more articles in the media than Adlai Nortye. MarketBeat recorded 4 mentions for Disc Medicine and 3 mentions for Adlai Nortye. Adlai Nortye's average media sentiment score of 0.92 beat Disc Medicine's score of 0.26 indicating that Adlai Nortye is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Disc Medicine	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Adlai Nortye	2 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Adlai Nortye has higher revenue and earnings than Disc Medicine.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Disc Medicine	N/A	N/A	-$212.18M	-$6.58	N/A
Adlai Nortye	$5M	206.53	-$35.53M	N/A	N/A

Adlai Nortye's return on equity of 0.00% beat Disc Medicine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Disc Medicine	N/A	-37.17%	-33.65%
Adlai Nortye	N/A	N/A	N/A

Summary

Adlai Nortye beats Disc Medicine on 7 of the 12 factors compared between the two stocks.

How does Disc Medicine compare to Sana Biotechnology?

Sana Biotechnology (NASDAQ:SANA) and Disc Medicine (NASDAQ:IRON) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, media sentiment, valuation, profitability, risk, analyst recommendations, dividends and institutional ownership.

Sana Biotechnology has a beta of 2.12, indicating that its share price is 112% more volatile than the broader market. Comparatively, Disc Medicine has a beta of 0.97, indicating that its share price is 3% less volatile than the broader market.

Disc Medicine is trading at a lower price-to-earnings ratio than Sana Biotechnology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sana Biotechnology	N/A	N/A	-$244.17M	-$0.76	N/A
Disc Medicine	N/A	N/A	-$212.18M	-$6.58	N/A

Disc Medicine's return on equity of -37.17% beat Sana Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sana Biotechnology	N/A	-103.02%	-39.16%
Disc Medicine	N/A	-37.17%	-33.65%

88.2% of Sana Biotechnology shares are held by institutional investors. Comparatively, 83.7% of Disc Medicine shares are held by institutional investors. 25.4% of Sana Biotechnology shares are held by company insiders. Comparatively, 3.8% of Disc Medicine shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

In the previous week, Disc Medicine had 1 more articles in the media than Sana Biotechnology. MarketBeat recorded 4 mentions for Disc Medicine and 3 mentions for Sana Biotechnology. Sana Biotechnology's average media sentiment score of 0.42 beat Disc Medicine's score of 0.26 indicating that Sana Biotechnology is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sana Biotechnology	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Disc Medicine	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Sana Biotechnology currently has a consensus price target of $9.33, indicating a potential upside of 205.51%. Disc Medicine has a consensus price target of $110.18, indicating a potential upside of 67.93%. Given Sana Biotechnology's stronger consensus rating and higher probable upside, analysts clearly believe Sana Biotechnology is more favorable than Disc Medicine.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sana Biotechnology	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.80
Disc Medicine	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.77

Summary

Sana Biotechnology beats Disc Medicine on 9 of the 14 factors compared between the two stocks.

Get Disc Medicine News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IRON and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

IRON vs. The Competition

Export

Metric	Disc Medicine	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$2.52B	$3.90B	$7.20B	$13.11B
Dividend Yield	N/A	3.64%	2.53%	13.00%
P/E Ratio	-9.96	14.44	274.69	25.74
Price / Sales	N/A	1,368.92	644.10	85.75
Price / Cash	N/A	109.50	76.31	52.02
Price / Book	3.36	15.27	10.44	6.31
Net Income	-$212.18M	-$22.82M	$3.49B	$359.73M
7 Day Performance	-4.32%	-0.14%	0.66%	1.59%
1 Month Performance	-17.79%	-5.96%	-3.30%	-3.46%
1 Year Performance	5.55%	34.98%	16.20%	5.79%

Disc Medicine Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
IRON Disc Medicine	2.0639 of 5 stars	$65.65 -4.1%	$110.18 +67.8%	+11.4%	$2.52B	N/A	N/A	165
KURA Kura Oncology	3.4119 of 5 stars	$11.30 -2.2%	$25.40 +124.8%	+45.0%	$1.01B	$67.48M	N/A	260
JANX Janux Therapeutics	3.0284 of 5 stars	$16.44 -5.0%	$36.46 +121.8%	-25.7%	$1.01B	$24M	N/A	113
ABUS Arbutus Biopharma	1.5787 of 5 stars	$5.06 -1.4%	$5.00 -1.2%	+13.1%	$1.00B	$14.08M	6.41	19	Positive News
ANL Adlai Nortye	2.5169 of 5 stars	$15.00 -5.8%	$29.50 +96.7%	+882.2%	$965.97M	$18.06M	N/A	109

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:IRON) was last updated on 9/23/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Disc Medicine (IRON) Competitors

IRON vs. KURA, JANX, ABUS, ANL, and SANA

How does Disc Medicine compare to Kura Oncology?

Summary

How does Disc Medicine compare to Janux Therapeutics?

Summary

How does Disc Medicine compare to Arbutus Biopharma?

Summary

How does Disc Medicine compare to Adlai Nortye?

Summary

How does Disc Medicine compare to Sana Biotechnology?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IRON vs. The Competition

Disc Medicine Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Disc Medicine (IRON) Competitors

IRON vs. KURA, JANX, ABUS, ANL, and SANA

How does Disc Medicine compare to Kura Oncology?

Does the media favor KURA or IRON?

Do institutionals and insiders hold more shares of KURA or IRON?

Which has preferable valuation & earnings, KURA or IRON?

Do analysts rate KURA or IRON?

Which has more volatility & risk, KURA or IRON?

Is KURA or IRON more profitable?

Summary

How does Disc Medicine compare to Janux Therapeutics?

Do insiders & institutionals believe in JANX or IRON?

Does the media favor JANX or IRON?

Which has preferable earnings & valuation, JANX or IRON?

Do analysts prefer JANX or IRON?

Which has more risk & volatility, JANX or IRON?

Is JANX or IRON more profitable?

Summary

How does Disc Medicine compare to Arbutus Biopharma?

Do institutionals and insiders hold more shares of IRON or ABUS?

Which has preferable earnings and valuation, IRON or ABUS?

Is IRON or ABUS more profitable?

Which has more risk and volatility, IRON or ABUS?

Does the media favor IRON or ABUS?

Do analysts prefer IRON or ABUS?

Summary

How does Disc Medicine compare to Adlai Nortye?

Do institutionals and insiders believe in IRON or ANL?

Do analysts prefer IRON or ANL?

Which has more risk & volatility, IRON or ANL?

Does the media favor IRON or ANL?

Which has higher valuation and earnings, IRON or ANL?

Is IRON or ANL more profitable?

Summary

How does Disc Medicine compare to Sana Biotechnology?

Which has more risk & volatility, SANA or IRON?

Which has better valuation and earnings, SANA or IRON?

Is SANA or IRON more profitable?

Do insiders & institutionals believe in SANA or IRON?

Does the media refer more to SANA or IRON?

Do analysts prefer SANA or IRON?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IRON vs. The Competition

Disc Medicine Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools